Intra-cellular therapies, inc. (ITCI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Revenue

60

-

245

330

91

577

2,737

3,117

License and collaboration revenue

-

-

-

-

30

547

2,737

3,117

Grant revenue

-

-

-

-

60

29

-

-

Operating expenses:
Research and development

89,124

132,166

79,419

93,831

87,718

21,226

23,027

15,486

General and administrative

64,947

30,099

23,666

24,758

18,187

10,337

5,976

4,034

Total operating expenses

154,072

162,266

103,085

118,589

105,905

31,564

29,003

19,521

Loss from operations

-154,011

-162,266

-102,840

-118,258

-105,813

-30,986

-26,266

-16,403

Interest income

6,291

7,140

4,005

2,935

1,022

303

29

39

Interest expense

-

-

-

36

-

7

612

193

Loss before provision for income taxes

-147,720

-155,125

-98,834

-115,360

-104,791

-30,689

-

-

Income tax expense

1

1

-1,060

1,065

1

1

18

32

Net loss

-147,722

-155,127

-97,773

-116,426

-104,793

-30,691

-26,868

-16,590

Net loss per common share:
Basic & Diluted

-2.68

-2.84

-2.12

-2.69

-2.91

-1.07

-1.56

-2.96

Weighted average number of common shares:
Basic & Diluted

55,186

54,707

46,181

43,240

36,069

28,650

17,260

5,607